HGG clinical trials at UCLA

1 research study open to eligible people

Showing trials for

  • FORE8394 in Participants With Cancer Harboring BRAF Alterations

    open to eligible people ages 10 years and up

    The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors harboring BRAF fusions, or in participants with rare BRAF V600-mutated solid tumors, melanoma, thyroid, or recurrent primary CNS tumors.

    Westwood, California and other locations

Our lead scientists for HGG research studies include .

Last updated: